Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events
Nathan D. Wong, PhD*,
Heidi Gransar, MS ,
Jagat Narula, MD, PhD*,
Leslee Shaw, PhD ,
Johanna H. Moon, MPH,
Romalisa Miranda-Peats, MPH,
Alan Rozanski, MD ,
Sean W. Hayes, MD,
Louise E.J. Thomson, MB, ChB,||,
John D. Friedman, MD,||,
Daniel S. Berman, MD,||,*
* Division of Cardiology, University of California, Irvine, California
Department of Imaging, Division of Nuclear Medicine, and Department of Medicine, Division of Cardiology, and the CSMC Burns & Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
Emory University School of Medicine, Atlanta, Georgia
Department of Cardiology, St. Luke's Roosevelt Hospital Center, New York, New York
|| Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Distribution of Myeloperoxidase Level (pM) by CAC Category
Mean levels of myeloperoxidase are shown according to CAC category (0 to 9, 10 to 99, 100 to 399, and  400). Cuzick's nonparametric test of trend p = 0.02 across CAC categories. CAC = coronary artery calcium.
|
|
View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Levels of MPO and CVD Event Risk (%)
The cumulative percentage of subjects with CVD events is shown according to MPO quartile. Log-rank test of trend p = 0.04 across MPO quartiles; p = 0.02 comparing those above (third and fourth quartiles) versus below (first and second quartiles) median. CVD = cardiovascular disease; MPO = myeloperoxidase.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Event Risk of CVD (%) by Combined MPO and CAC Group
The cumulative proportion of subjects with CVD events is shown according to combined MPO and CAC group; log-rank test for trend p < 0.001. Abbreviations as in Figures 1 and 2.
|
|
|
